SUDA Pharmaceuticals Ltd (ASX:SUD) has attained a significant milestone with the receipt of Therapeutics Goods Administration’s (TGA) approval for its lead product ZolpiMistTM for treating short-term insomnia in adults.
TGA approval provides following benefits to SUDA:
- It enables commercialisation and supply of product within Australia.
- It allows more competitive supply price for the product.
- It supports corresponding submissions in additional territories.
Following the key update, SUDA’s stock is trading ~203.7 per cent higher at $0.082 (as at 12:00 PM AEST)
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.